Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2010-01-20
2011-11-08
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C435S007100, C530S350000
Reexamination Certificate
active
08052960
ABSTRACT:
Detection and diagnosis of injury and/or disease in a subject can be key to preventing irreversible damage and death. Methods of aiding detection and assessment of a disease or condition in a subject are which include assaying netrin-1 protein and/or nucleic acid in a test sample obtained from the subject. Methods of assessment of treatment of a disease or condition in a subject are provided which include assaying netrin-1 protein and/or nucleic acid in a test sample obtained from the subject. Disclosed methods allow for earlier detection of renal dysfunction compared to currently available technology.
REFERENCES:
patent: 5565331 (1996-10-01), Tessier-Lavigne et al.
patent: 6309638 (2001-10-01), Tessier-Lavigne et al.
patent: 6670451 (2003-12-01), Tessier-Lavigne et al.
patent: 7141382 (2006-11-01), Parikh et al.
patent: 7456151 (2008-11-01), Li et al.
patent: 2006/0019896 (2006-01-01), Li et al.
patent: 2006/0025335 (2006-02-01), Kinane et al.
patent: 2006/0153840 (2006-07-01), Eichmann et al.
patent: 2006/0246495 (2006-11-01), Garrett et al.
patent: 2009/0226458 (2009-09-01), Mehlen et al.
patent: 2010/0040622 (2010-02-01), Li et al.
patent: WO-2007/099133 (2007-09-01), None
patent: WO-2009/141440 (2009-11-01), None
Ahlström, A. et al, Evolution and predictive power of serum cystatin C in acute renal failure,Clinical Nephrology, 62(5):344-350, Nov. 2004 (Abstract only).
Basnakian, A.G., Netrin-1: a potential universal biomarker for acute kidney injury,Am Journal of Physiol Renal Physiol., 294(4): F729-30, Apr. 2008, Epub Feb. 27, 2008.
Coca, S.G. et al., Biomarkers for the diagnosis and risk stratification of acute kidney injury: A systemic review,Kidney International, 73:1008-1016, 2008.
Devarajan, et al. Proteomics for Biomarker Discovery in Acute Kidney Injury,Semin Nephrol., 27(6):637-651, Nov. 2007.
Edelstein, C.L., Biomarkers of acute kidney injury,Advances in Chronic Kidney Disease, 15(3): 222-234, 2008 (Abstract only).
Geisbrecht et al., Netrin Binds Discrete Subdomains of DCC and UNC5 and Mediates Interactions between DCC and Heparin,The Journal of Biological Chemistry, 278(35):32561-68, Aug. 29, 2003.
Han, W.K. et al. Kidney Injury Molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury,Kidney International, 62: 237-244, 2002.
Mishra, J. et al., Identification of Neutrophil Gelatinase-Associated Lipocalin as a Novel Early Urinary Biomarker for Ischemic Renal Injury,Journal of the American Society of Nephrology, 14: 2534-2543, 2003.
Mishra, J. et al., Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery,Lancet, 365(9466):1231-8, Apr. 2005 (Abstract only).
Noiri, E. et al., Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injury,American Journal Physiology, Renal Physiology, 296: F669-679, 2009 (Abstract only).
Reeves, et al., Netrin-1 and Kidney Injury. II. Netrin-1 is an early biomarker of acute kidney injury,Am Journal of Physiol Renal Physiol., 294(4): F731-8, Apr. 2008, Epub Jan. 30, 2008.
Wang, W. et al., Netrin-1 and Kidney Injury. I. Netrin-1 protects against ischemia-reperfusion injury of the kidney,Am Journal of Physiol Renal Physiol., 294(4): F739-47, Apr. 2008, Epub Jan. 23, 2008.
Zhou, H. et al., Exosomal Fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury,Kidney International, 70(10):1847-1857, Nov. 2006.
Apotech, Manual: Netrin-1 (human) Detection Set (for ELISA Application), Version 1, dated Dec. 5, 2008.
Ramesh, G. et al., Netrin-1: A Novel Universal Biomarker of Human Kidney Injury, Transplantation Proceedings, 42: 1519-22, 2010.
Arakawa, H., Netrin-1 and its Receptors in Tumorigenesis,Nature Reviews—Cancer, 4(12): 978-87, Dec. 2004 (Abstract only).
Delloye-Bourgeois, C. et al., Interference with Netrin-1 and Tumor Cell Death in Non-Small Cell Lung Cancer,Journal of the National Cancer Institute, 101: 237-247, 2009.
Fitamant, J. et al. Netrin-1 Expression Confers a Selective Advantage for Tumor Cell Survival in Metastatic Breast Cancer,PNAS, 105(12): 4850-55, Mar. 25, 2008.
Mehlen, P. et al., Role of Netrin-1 and Netrin-1 Dependence Receptors in Colorectal Cancers,British Journal of Cancer, 93: 1-6, 2005.
Schön, M. et al., To Die or Not to Die, That's the Question—And the Answer May Depend on Netrin-1,Journal of the National Cancer Institute, 101(4): 217-19, Feb. 18, 2009.
P. Mehlan et al., U.S. Appl. No. 61/055,049, filed May 21, 2008, entitled “Netrin-1 Overexpression as a Biological Marker and a Survival Factor for Aggressive Neuroblastoma”.
(Author unknown), Human Netrin-1, Ntn1 ELISA Kit, Catalot No. E1827h, (believed to have been offered for sale, publicly used, and/or published as early as Sep. 30, 2008).
Ramesh, G. et al., Endotoxin and Cisplatin Synergistically Induce Renal Dysfunction and Cytokine Production in Mice,American Journal of Physiology—Renal Physiology, 293: F325-32, May 2007.
Gifford Krass Sprinkle Anderson & Citkowski P.C.
Lockard Jon M
Saoud Christine J
The Penn State Research Foundation
LandOfFree
Netrin-1 as a biomarker of injury and disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Netrin-1 as a biomarker of injury and disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Netrin-1 as a biomarker of injury and disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4266155